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Introduction: DNA methylation is part of the epigenetic regula-
tory mechanism present in all normal cells. It is tissue-specific and 
stably maintained throughout development, but often abnormally 
changed in cancer. Non–small-cell lung carcinoma (NSCLC) is the 
most deadly type of cancer, involving different tumor subtypes. This 
heterogeneity is a challenge for correct diagnosis and patient treat-
ment. The stability and specificity make of DNA methylation a very 
suitable marker for epigenetic phenotyping of tumors.
Methods: To identify candidate markers for use in NSCLC diagno-
sis, we used genomewide DNA methylation maps that we had previ-
ously generated by MethylCap and next-generation sequencing and 
listed the most significant differentially methylated regions (DMRs). 
The 25 DMRs with highest significance in their methylation scores 
were selected. The methylation status of these DMRs was investi-
gated in 61 tumors and matching control lung tissues by methylation-
specific polymerase chain reaction.
Results: We found 12 novel DMRs that showed significant differ-
ences between tumor and control lung tissues. We also identified 
three novel DMRs for each of the two most common NSCLC sub-
types, adenocarcinomas and squamous cell carcinomas. We propose 
a panel of five DMRs, composed of novel and known markers that 
exhibit high specificity and sensitivity to distinguish tumors from 
control lung tissues.
Conclusion: Novel markers will aid the development of a highly 
specific epigenetic panel for accurate identification and subtyping of 
NSCLC tumors.
Key Words: epigenetic markers, DNA methylation, genomewide, 
MSP, non–small-cell lung cancer
(J Thorac Oncol. 2013;8:562-573)
DNA methylation is an epigenetic modification present in the genome and an essential regulatory mechanism 
involved in crucial processes for normal development.1,2 It 
is an important player in chromatin structure, where wide-
spread methylation in the DNA leads to the formation of 
heterochromatin.3 Another process involving DNA meth-
ylation is the silencing of viral and repetitive elements that 
have been incorporated in the genome over time.4,5 DNA 
methylation patterns are tissue specific and these patterns 
are stably inherited.6
It is known that tumor cells often display methylation 
patterns different from their normal counterparts.7 Therefore, 
many studies have focused on finding and quantifying these 
differences.8–13 To date, many genes are known to be aber-
rantly methylated in virtually all types of cancer. Epigenetic 
inactivation of tumor suppressor genes by DNA hypermethyl-
ation is believed to be an early and frequent event in oncogen-
esis.14,15 Tumor suppressor genes, such as RASSF1, CDKN2A, 
DAPK, APC, and p14, are aberrantly methylated in a vari-
ety of cancers,16–20 including non–small-cell lung carcinoma 
(NSCLC).14,21–25
Considering both genders, NSCLC is the cancer with 
the highest incidence and mortality rates worldwide.26 It is 
also a very heterogeneous malignancy, involving different 
tumor subtypes. According to the World Health Organization, 
NSCLC can be broadly divided into three major groups: 
adenocarcinoma (ADC), squamous cell carcinoma (SCC), 
and large cell carcinoma (LCC). Within these three groups, 
and including other less frequent types, NSCLC presents 
more than 30 histopathological subtypes.27 This heterogeneity 
forms a great problem for diagnosis, which is currently based 
on histological classification aided by immunohistochemical 
staining.28 This degree of variability presents a challenge for 
unambiguous histological classification of NSCLC cases. 
At present, chemotherapeutic agents and targeted agents are 
selected through histology. In the United States, bevacizumab, 
the primary treatment in metastasized NSCLC is only 
registered for the treatment of ADC. Also pemetrexed was 
shown to be most effective in nonsquamous carcinoma.29–31 
Therefore, correct histological classification is important in 
choosing treatment and patient outcome.
Genetic and epigenetic studies show that tumors 
belonging to the same traditional histological classification 
present different molecular signatures.28,32,33 This indicates 
that, although the tumors are part of the same group, they 
may present different etiologies, behave differently in growth, 
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predisposition to develop metastasis and also respond differ-
ently to treatment.
Data on methylated genes in NSCLC has been accu-
mulating over recent years;13,34–36 however, not only the iden-
tified methylated loci differ between studies, but also the 
level of methylation observed at these loci is often divergent. 
Although methylation of certain genes has been observed 
to be different between control lung and NSCLC25,37 and 
between NSCLC subtypes,37,38 sets of methylation markers 
able to discriminate these with high specificity and sensitiv-
ity are still elusive.
We have recently performed genomewide methylation 
profiling of NSCLCs, where we identified differentially meth-
ylated regions (DMRs) in tumors when compared with match-
ing control lung tissue. Among the DMRs identified there 
were several regions which seemed to be tumor and subtype 
specific. Here, we used selected DMRs to screen 61 NSCLC 
tumors and matching control lung tissues using methylation-
specific polymerase chain reaction (MSP). We investigated 
the potential of 25 these DMRs to distinguish tumor from 
control lung tissue with high specificity and sensitivity and 
to discriminate between the two most common NSCLC sub-
types: ADC and SCC.
MATERIALS AND METHODS
Patient Samples and Histopathological Analysis
Samples were obtained from 61 patients diagnosed 
with NSCLC who had undergone surgical lung resection at 
Erasmus MC. Tissues from the tumor and adjacent noncan-
cerous lung were collected and snap-frozen in liquid nitrogen 
precooled isopentane within 2 hours after surgical resection. 
Samples were stored at −196°C or −80°C until DNA extrac-
tion. Patient history, histology of NSCLC samples and immu-
nohistochemistry for epidermal growth factor receptor, tumor 
protein p53, tumor protein p63, thyroid transcription factor 1, 
xenotropic and polytropic retrovirus receptor 1 (SYG), neural 
cell adhesion molecule 1, chromogranin A, and keratin 5 were 
described previously.32,33
The cohort included 20 ADC, 27 SCC, 10 LCC, and 
four unclassified samples; paired noncancerous lung tissues 
that were used as controls. The percentage of tumor cells was 
determined previously by a lung pathologist32 and was on 
average 67.1 ± 19.62% (range, 20%–80%). Specimens were 
collected and studied under an anonymous tissue protocol 
approved by the local Erasmus MC medical ethical committee.
Cell Line
The MRC-5 lung fibroblastlike cell line was used. Cells 
were cultured under standard conditions. In short: minimum 
essential medium supplemented with 10% heat-inactivated fetal 
bovine serum, 2 mM L-glutamine, 1% nonessential amino acids, 
and penicillin/streptomycin; incubated at 37°C and 5% carbon 
dioxide. Cells were harvested when they reached 90% confluence.
DNA Isolation
Genomic DNA from patient tissues and cultured cells 
were extracted by overnight incubation with a lysis buffer and 
proteinase K, followed by phenol-chloroform extraction, etha-
nol precipitation, and RNase digestion.
Artificial Demethylation and 
Methylation of Genomic DNA
We used DNA extracted from the MRC-5 cell line and 
commercially available universal unmethylated DNA (UUD, 
Millipore, Billerica, MA). Fully unmethylated DNA was 
obtained by whole-genome amplification using the REPLI-g 
kit (Qiagen, Germantown, MD) according to manufacturer 
protocol, followed by phenol-chloroform extraction. Fully 
methylated DNA was prepared by treating MRC-5 DNA 
and UUD with the M.SssI enzyme (New England Biolabs, 
Ipswich, MA) according to the manufacturer’s protocol. In 
short, 10 µg of DNA was incubated for 2 hours at 37°C with 
40 U of M.SssI and 640 µM of S-adenosylmethionine. DNA 
was then treated with phenol-chloroform and recovered by 
ethanol precipitation.
MSP
We used MSP11 to determine the methylation status of 
the 25 selected regions in 122 samples (61 tumors and match-
ing healthy tissues). Samples were bisulfite converted using 
the Epitect kit from Qiagen (Germantown, MD) following 
the manufacturer’s protocol. Samples were amplified using 
two different set of primers designed for the methylated and 
unmethylated sequences. Primers and amplification condi-
tions are specified in Supplementary Table 1 (Supplemental 
Digital Content 1, http://links.lww.com/JTO/A394). The fully 
methylated and fully unmethylated DNA samples were used as 
controls, and water blank reactions were used as controls for 
contamination. After amplification, products were resolved on 
2% agarose gels containing ethidium bromide.
Band counts and intensities. Gels were scanned using a 
Typhoon Trio or Typhoon 9410 Scanner from GE Health Care 
(Chalfont St Giles, United Kingdom) with settings as fol-
lows: filter 610 BP 30; green (532 nm); photo-multiplier tube 
voltage (PMT) varying between 580 and 610 V; focal plane 
+3 mm; pixel size: 200 μm. Intensities of the bands were cal-
culated using the analysis tool box of ImageQuantTL software 
(GE Healthcare Life Sciences, Pittsburgh, PA). Volume report 
for each band was obtained by calculating pixels intensities 
within each band (I) and subtracting from the background. 
The background was determined by the equivalent area above 
(bg1) and below each band (bg2). We obtained the real inten-
sity of each band by extracting the band volume from the 
background volume (raw intensity). Values for all DMRs in all 
samples can be found in Supplemental File 1 (Supplemental 
Digital Content 2, http://links.lww.com/JTO/A394).
Normalization of Intensities
We used the fully methylated and fully unmethylated 
control samples for determination of maximum and minimum 
intensity in each fragment. Normalization was calculated by 
the amplification ratio between the fully methylated and fully 
unmethylated samples intensities. We also generated a correction 
coefficient for the primers. For this, we amplified mixtures of 
the fully methylated and fully unmethylated control samples 
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(100/0–80/20–60/40–50/50–40/60–20/80–0/100) with each 
primer pair for each fragment. Efficiency curves were 
generated and the band intensities of the control samples 
corrected based using the slope and intercept values of the 
generated curves. The correction coefficient for methylated 
and unmethylated primers was then calculated as the ratio 
between “methylated” and “unmethylated” amplification 
products at each point based in the corrected band intensities 
of controls. Using this coefficient, intensities of the bands 
for the tested samples were adjusted for each fragment and 
corrected for differences in primer efficiencies.
Statistical Analysis
We used PASW 18.0 statistical software (SPSS Inc., 
Chicago, IL) for analysis. We applied Fisher’s exact test con-
sidering a 95% confidence interval (CI) and a two-sided p 
value (p[O ≥ E|O ≤ E]) for calculating the significance of dif-
ferences in methylation status by band counts for each DMR 
in control lung versus tumor/SCC/ADC samples. For MSP 
intensities and percentages we used the paired t test (95% CI) 
for significance between control lung and tumor samples, and 
the Mann-Whitney test for SCC versus ADC DMRs. Analysis 
of variance was used to compare control lung and tumor sam-
ples using combinations of DMRs. Sensitivity was defined as 
the proportion of tumor samples that showed methylation of a 
specific DMR. Receiver operating characteristic (ROC) curve 
was produced and the area under the ROC curve (AUC-ROC) 
used for calculating specificity/sensitivity for each DMR. For 
each DMR, specificity was defined as the proportion of control 
(matching) lung samples lacking methylation and sensitivity 
as the proportion of tumor samples displaying methylation. 
Logistic regression with 95% CI was used for calculating the 
sensitivity and specificity of marker panels.
RESULTS
Selection of Differentially Methylated Regions 
for Analysis by Methylation-Specific PCR
For screening a larger number of samples (n = 61), we 
selected 25 DMRs (Table 1) from the list of most differen-
tially methylated regions that we had previously identified by 
MethylCap-seq.39 Among these 25 DMRs, 10 were present in 
all seven tumors used for the MethylCap-seq assays (3 SCC, 
3 ADC, and 1 LCC), five seemed to be specific for the three 
SCC samples, and another five seemed to be specific for the 
three ADC samples. The remaining five DMRs were used for 
validation in our previous study39 and are therefore included 
here. Selection was principally based on five criteria: (1) 
regions with the highest two-log ratio across all samples of the 
group of interest (all tumors, SCC or ADC); (2) length of the 
region spanned by the DMR which presented as significant (p 
≤ 10–18). Because relative methylation scores were calculated 
based on 500 base pair (bp) bins, each DMR is represented by 
a 500-bp window. Regions that showed more than one serially 
significant DMR were preferred; (3) region of the gene where 
methylation was observed: promoter, 3′UTR, or gene body; 
(4) likelihood of the gene to play a role in tumorigenesis, and 
(5) novelty of the region.
Figure 1 shows eight of the 25 DMRs for one paired 
sample (control lung versus tumor), where multiple DMRs are 
observed in each fragment. Among the 25 selected DMRs, one is 
located within a genomic region about 10 kb upstream from the 
EN1 gene (chr2:119328097-1193284, referred to as Frag_01). 
Because we observed that this highly differentially methylated 
genomic region located at 2q14.2 spanned more than 25 kb 
(chr2:119,307,647-119,333,875), another two regions were 
selected: Frag_02 (chr2:119331343-119331692) and the pro-
moter of the EN1 gene (Fig. 1F). RASSF1 was selected because 
it is frequently reported as methylated in NSCLC.40–43
The RASSF1, Frag_02, and EN1 promoters did not 
appear in the list of DMRs because their p values are −14.71, 
−17.63, and −17.58, falling outside the cutoff p value less than 
or equal to 10–18.
Methylation Profiles by MSP
We performed MSP for determining the methylation 
status of all 25 DMRs in the 61 primary tumors and match-
ing control lung tissues (summarized in Fig. 2). MSP gel 
images for all fragments and all samples can be found in 
Supplemental File 02 (Supplemental Digital Content 3, http://
links.lww.com/JTO/A394). For this, we used two sets of prim-
ers for each DMR: one set (M) requires methylated DNA, the 
other (U) requires unmethylated DNA for amplification. We 
counted the numbers of samples that showed amplification for 
each of the primers, considering any amplification as 1 and no 
amplification as 0 (all counts are shown in Supplemental Table 
2, Supplemental Digital Content 4, http://links.lww.com/JTO/
A394.) We then calculated the percentages of samples that 
were amplified with the M or U primers (Table 2).
We found that PARP15, CDKN2A, HIS1H3C, 
ANKRD1B, DOT1L, GAS1, and SEPT9 presented no signifi-
cant difference between control lung samples and tumors, con-
sidering that a p value is less than 0.001. PARP15, CDKN2A, 
HIST3B, and ANKRD1B were selected as tumor DMRs and 
showed high sensitivity but low specificity, whereas DOT1L, 
GAS1, and SEPT9 were selected as subtype DMRs. GAS1 and 
DOT1L showed a moderate specificity and sensitivity for dif-
ferentiating between control lung samples and tumors, and 
SEPT9 low sensitivity but very high specificity. We observed 
that the control lung samples were methylated for CDKN2A 
and PARP15 in more than 90% of the cases, although the lev-
els of methylation were lower compared with those observed 
in the matching tumors (Fig. 3A). This was also observed for 
DOT1L and GAS1, although the sensitivity of these DMRs 
was lower. HISTH3B and ANKRD1B were removed from fur-
ther analysis because both were methylated in more than 90% 
of the control lung samples, with no difference observed in 
degree of amplification (Fig. 3B). Although SEPT9 had very 
low sensitivity, there was no amplification in normal samples.
For the remaining 10 DMRs, we observed that the 
difference between methylation status of control lung samples 
and tumor samples was highly significant. We found that the 
percentage of tumor samples methylated for RASSF1 in our 
cohort is in agreement with previous reports.40–43 All other 
DMRs tested had a high percentage of methylation in tumors, 
varying from 100% to 72%. Regarding the DMRs selected 
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for histological subtypes (Table 3), one of the ADCs DMRs 
(FAM78B) was highly significant (p < 0.001) to discriminate 
between SCC and ADC, whereas other two ADC DMRs (MSC 
and GAS1) and a SCC DMR (DOT1L) showed a moderate 
significance (0.001 < p < 0.01). GAS1 and DOT1L were 
methylated in 63.3% and 40.7% of the control lung samples, 
respectively. It is therefore possible that hypermethylation 
of these markers reflects stromal contamination of the 
tumors. However, we did not find any correlation between 
the percentage of tumor cells and the methylation status of 
GAS1 and DOT1L in the NSCLC samples. We observed 
that the DMRs selected for histological subtype presented a 
lower potential to discriminate between the two histological 
subtypes than between control lung and tumor samples.
Semiquantitative MSP: Intensities and 
Percentages of Methylated DNA Per Sample
Because we observed that amplification levels with 
methylated primers were often lower in control lung samples 
than in their paired tumor tissues, we decided to measure 
the band intensity of each sample and determine whether 
this difference was significant. We scanned the gels using a 
Typhoon 9410 scanner and used ImageQuant software (GE 
Healthcare Life Sciences, Pittsburgh, PA) to determine the 
intensity of each band. For this we selected each individual 
band (sample) and the equivalent area above and below 
each (individual background). We then calculated the pixel 
intensities by subtracting the intensities of the individual 
backgrounds from those obtained for the samples. Intensities 
of unmethylated and methylated fragments were normalized 
using a correction coefficient for primer efficiency calculated 
from the fully methylated and fully unmethylated control 
sample (Supplemental Table 3, Supplemental Digital content 
5, http://links.lww.com/JTO/A394, shows all correction 
coefficients used per primer in all fragments.)
Distributions of the intensities of each DMR with the 
methylation primer are shown in Figure 4 (all intensities 
values can be viewed in Supplemental File 3, Supplemental 
Digital Content 6, http://links.lww.com/JTO/A394). Although 
TABLE 1.  DMRs Selected From the Genomewide Methylation Profiles
DMR
Log
2 
Ratio of RMS Tumor Versus Lung Sample
Gene Region
HGNC 
ID Gene ClassSCC1 SCC2 SCC3 ADC1 ADC2 ADC3 LCC
Tumor DMRs
 BARX1 6.96 5.10 4.36 4.46 4.20 4.22 3.99 Body 955 Transcription regulator
 DMRTA2 2.99 3.16 4.44 2.15 2.78 1.92 4.32 Body 13908 Transcription regulator
 FGF12 3.52 6.67 3.95 2.94 3.17 1.49 4.21 Promoter 3668 Growth factor
 GATA3 2.75 4.13 3.10 2.97 2.82 2.12 3.01 Promoter 4172 Transcription regulator
 GRIK2 5.34 1.63 3.91 1.22 1.74 1.75 3.31 Promoter 4580 Ion channel
 ONECUT2 3.73 3.84 5.86 2.84 3.04 1.98 3.92 Body 8139 Transcription regulator
 PARP15 2.86 2.91 2.77 3.94 2.50 2.51 2.48 Promoter 26876 Transcription regulator
 PRDM14 4.23 3.81 3.77 3.65 5.36 1.48 2.43 Promoter 14001 Transcription regulator
 RAX 5.22 2.92 4.18 2.31 2.81 1.77 5.48 Promoter 18662 Transcription regulator
 TBX15 3.54 2.36 3.26 2.48 1.91 1.60 1.27 Body 11594 Transcription regulator
SCC DMRs
 ZIC4 7.69 2.38 6.58 0.00 0.00 −0.15 0.00 Promoter 20393 Transcription regulator*
 DOT1L 3.61 6.32 4.65 0.00 0.00 0.00 0.00 First intron 24948 Chromatin regulator
 LIMK1 4.30 5.51 4.44 0.00 0.00 0.00 −0.98 Body 6613 Cell organization
 ANKRD13B 6.57 4.49 3.74 0.00 0.00 0.00 0.00 3′UTR 26363 Unknown
 HIST1H3C 3.44 4.45 6.99 0.00 0.00 0.00 0.00 Promoter 4768 Histone protein
ADC DMRs
 MSC 0.00 0.00 0.00 2.98 5.58 4.66 0.00 Promoter 7321 Transcription regulator
 GAS1 0.00 0.00 0.00 2.06 2.79 4.94 0.00 Promoter 4165 Cell cycle/growth
 HOXA1 0.00 0.00 0.00 3.96 2.88 3.86 0.00 Promoter 5099 Transcription regulator
 SEPT9 0.00 0.00 0.00 5.35 3.02 1.44 0.00 Body 7323 Enzyme
 FAM78B 0.00 0.00 0.00 5.02 4.30 2.96 0.00 First intron 13495 Unknown
 CDKN2A 2.73 2.73 5.72 0.75 −1.16 1.78 0.00 3′UTR 1787 Tumor suppressor
 RASSF1 NA NA NA NA NA NA NA Promoter 9882 Tumor suppressora
 EN1 NA NA 0.00 NA NA NA 0.00 Promoter 3342 Transcription regulator
 Frag_01 5.09 4.21 2.64 0.00 0.00 0.00 0.00
 Frag_02 NA NA NA 0 NA NA 0.00
ADC, adenocarcinoma; DMR, differentially methylated regions; HGNC ID, HUGO gene nomenclature committee; NA, not available; SCC, squamous cell carcinoma; RMS, 
relative methylation score.
aPutative.
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a large variation between tumors was observed, the difference 
in methylation intensities was highly significant between con-
trol lung and tumor samples for all DMRs (Fig. 4A), includ-
ing CDKN2A and PARP15, which were not significant for the 
band counts alone because approximately 90% of control lung 
samples showed amplification with the M primer. By inten-
sities, these two fragments were highly significant to differ-
entiate between control lung and tumor. For the histological 
DMRs (Fig. 4B), we found that the intensities of amplified 
bands followed in general the same trend as observed for the 
band counts. FAM78B and GAS1 are capable of differentiat-
ing ADC from SCC, whereas DOT1L intensities were more 
significant in distinguishing SCC versus ADC (Fig. 4C). The 
other DMRs were not representative for either ADC or SCC.
Considering that significance was found for all tumor 
DMRs, we used the band intensities for methylated and 
unmethylated primers to calculate the level of DNA methyla-
tion (percentage) in each sample (Fig. 5 and Supplemental File 
4, Supplemental Digital Content 7, http://links.lww.com/JTO/
A394). For this we established M + U = 100%. We then divided 
the intensity of the ‘M’ bands by the sum of the intensities of 
the M and U bands (M/(M + U)). For all DMRs, we found 
that the calculated percentage of methylation was significantly 
higher in tumors than in control lung samples (Fig. 5A). The 
percentage of DNA methylation as reflected by the intensity 
of the bands displayed a large variation between the tumor 
samples. However, the median difference of DNA methylation 
between tumor and control lung samples is higher using per-
centages than intensities. This is observed because calculation 
of percentages takes both: methylated and unmethylated DNA 
content per sample into account. Only PRDM14 and RASSF1 
were less significant using percentages rather than intensities.
Tumor Markers
Next, we wished to determine which group of DMRs 
would give the best tumor prediction. As standard methodology 
for MSP is based on band counts, we used this method to 
develop tumor predictors. We calculated tumor specificity and 
sensitivity for each DMR by logistic regression to estimate 
the best panel of markers to differentiate between tumor and 
control lung samples. We found a five-marker panel composed 
of FGF12, GATA3, RAX, TBX15, and RASSF1 that predicted 
tumors with 100% specificity and 94% sensitivity (Table 4). 
Using a test set with 63 samples and three different methods 
FIGURE 1.  Methylation reads for selected DMRs. Methylation reads for selected differentially methylated regions (DMRs). 
UCSC genome browser representation of MethylCap-seq reads in eight DMRs for a paired sample: control lung (2231N) and 
tumor (2214T). Light green: region significantly differentially methylated; light red: region selected for methylation-specific 
polymerase chain reaction (MSP). y-Axis: number of reads ranging from 0 to the maximum number of reads in the highest peak 
in the selected window per sample. (A) DMRs in the BARX1 (1) gene spanning more than 3000 base pairs (bp), with 500 bp 
significant bin and 172 bp MSP fragment. (B) DMRs in the PRDM14 (2) gene spanning from 5′UTR to first exon (promoter 
region) with a 1000-bp bin and 194-bp MSP fragment. (C) DMRs in the DMRTA2 (3) gene with a 1000-bp significant bin and 
155 bp MSP fragment. (D) DMRs in the ZIC4 (4) gene in the promoter and first exon, showing a 500-bp significant bin in the 
promoter and 209-bp MSP fragment. (E) DMRs in the promoter region of the GRIK2 (5) gene, with a 500-bp bin and 179-bp 
MSP fragment. (F) Methylation of the EN1 gene showing DMRs spanning more than 25 kbp, and 500-bp bin approximately 
10 kbp upstream of the gene and three MSP fragments at 10 kbp upstream (6), 6 kbp upstream (7), and the EN1 promoter (8) 
(119, 192, and 214 bp, respectively).
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(partitioning around medoids, support vector machines, and 
nearest centroid) we could correctly predict 57 to 60 of the 63 
cases, respectively. This shows that this panel of five markers 
has a high predictive value for identification of tumors.
DISCUSSION
Many methods have been developed to investigate site-
specific methylation, but the simplest and widest used is MSP. 
In this study, we assessed the methylation status of 25 DMRs 
in 61 NSCLC patients, comparing methylation differences in 
tumors and matching control lung tissues by MSP. We selected 
genes and genomic regions based on genomewide methyla-
tion profiles we have performed in seven of these 61 patients, 
and focused on novel or infrequently reported genes. As a ref-
erence, we used CDKN2A and RASSF1, which have been fre-
quently reported as being methylated in NSCLC14,41,42,44
When using band counts, we found that the methyla-
tion status of CDKN2A and PARP15 were unable to differen-
tiate between control lung and tumor samples, although we 
observed a much lower methylation level in control lung sam-
ples than in the tumors. CDKN2A hypermethylation is known 
as an early event in carcinogenesis;14,21therefore, tissues that 
seem histologically normal may already present early cellu-
lar transformations that will eventually lead to oncogenesis. 
Although methylation rates in the paired lung and tumor tis-
sues were not significant for these two genes, when we mea-
sured the percentages of DNA methylation in control lung and 
tumor samples we observed a highly significant difference 
between the paired tissues. Of note, we observed a highly 
similar pattern between the PARP15 gene and CDKN2A. Poly 
(ADP-ribose) polymerase (PARP) is a family of transcrip-
tion regulators playing an important role in cellular processes 
such as DNA repair and apoptosis.45–47 PARP1 promoter 
hypermethylation has been reported to be involved in leuke-
mogenesis.48 Little is known about the other proteins of the 
same family, including PARP15 and its role in tumorigen-
esis or its methylation status in NSCLC. Here, we found that 
PARP15 is hypermethylated in all seven tumors investigated. 
Considering the importance of this family of proteins in regu-
lating key pathways involved in oncogenesis,49–53 our findings 
suggest that, similar to CDKN2A, PARP15 hypermethylation 
may be an early event in tumorigenesis. Further research is 
needed to test this hypothesis. In addition to CDKN2A and 
PARP15, we found GRIK2, GATA3, DMRTA2, RAX, Frag01, 
Frag02, EN1, TBX15, FGF12, LIMK1, ONECUT2, ZIC4, 
and BARX1 among the DMRs with highest sensitivity and 
specificity, and highly significant using either band counts or 
DNA methylation percentage as the method to assess meth-
ylation status.
As we focused on genes that were poorly or not at all 
reported as methylated in cancer and/or NSCLC, not much 
is known about them or the role that methylation of these 
genes plays in tumorigenesis. We note that many of the genes 
are members of the large homeobox family of transcription 
factors, such as RAX and BARX1 or genes known to have 
some involvement in neural development or neurotransmitters 
as example of DMRTA2, ZIC4, and GRIK2. Transcription 
factors makes the majority of the DMRs found in our previous 
study39; therefore some of those were here investigated.
FIGURE 2.  Representation of methylation-specific polymerase chain reaction (MSP) screening. (A) Cropped gel image of 
three paired samples and controls for all DMRs used. Meth: totally methylated control; Unmeth: totally umethylated control; 
M: primer for methylated CpG; U: primer for unmethylated CpG. (B) Control lung samples show less intense amplification of 
PARP15 and CDKN2A MSP fragments than matching tumor samples. (C) Intensities of HIST1H3B and ANKRD1B MSP fragments 
in control lung samples are not significantly different from those observed in matching tumor samples. Arrows point to methyl-
ated primers in control lung and tumor samples. DMRs, and differentially methylated regions.
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Homeobox genes such as RAX and BARX1 are highly 
hypermethylated in our cohort. We found hypermethylation of 
RAX in 82% of the tumor samples, although it was methylated 
in only 1 of 60 control lung samples. In a recent report, 
RAX was found to be methylated in human astrocytomas.54 
BARX1 is another homeobox transcription regulator. A recent 
study in colorectal cancer found promoter hypermethylation 
of BARX1 in 56% of the patients.55 In our study, this gene 
is methylated in 82% of the tumors and in only two of the 
control lung tissues. ZIC4 is poorly characterized gene, whose 
involvement in central nervous system development has been 
studied. Genetic alterations in this gene cause congenital 
cerebellar malformation.56 Promoter hypermethylation of 
ZIC1, another member of this family, was observed in gastric 
and colorectal cancer,57,58 whereas methylation of ZIC4 in 
NSCLC or other types of cancer has not been previously 
reported. ZIC4 methylation status was investigated in 57 
control lung samples and paired tumors, and we found no 
methylation in the normal lung tissues although the gene was 
methylated in 70% of the tumors.
Frag01 and Frag02 are genomic regions located on 
chromosome 2 q14.2. We have found that a large region 
FIGURE 3.  Differences in amplification intensities for methyl-
ated primer in control lung and matching tumor samples. (A) 
Control lung samples show less intense amplification of  
PARP15 and CDKN2A methylation-specific polymerase chain 
reaction (MSP) fragments than matching tumors samples. 
(B) Intensities of HIST1H3B and ANKRD1B MSP fragments in 
control lung samples in are not significantly different those 
observed in matching tumor samples. Red arrows point to 
methylated primers in control lung and tumor samples.
TABLE 2.  Methylation Status of Lung Versus Tumor for All DMRs
Methylation Status (M primer)
Total (n)
Lung Tumor
p Valuen % n %
BARX1 56 2 3.57 46 82.14 8.82E−19
FGF12 61 1 1.64 44 72.13 1.16E−17
PRDM14 53 5 9.43 43 81.13 2.92E−14
RAX 60 1 1.67 49 81.67 2.25E−21
DMRTA2 61 2 3.28 44 72.13 2.09E−16
ONECUT2 59 3 5.08 49 83.05 3.87E−19
PARP15 59 55 93.22 59 100.00 1.19E−01
GATA3 56 2 3.57 44 78.57 2.63E−17
GRIK2 60 7 11.67 54 90.00 4.13E−19
TBX15 60 12 20.00 57 95.00 3.85E−18
CDKN2A 60 55 91.67 60 100.00 5.73E−02
RASSF1 56 0 0.00 23 41.07 1.37E−08
ZIC4 57 0 0.00 40 70.18 2.96E−17
DOTL1 60 38 63.33 53 88.33 2.40E−03
LIMK1 56 1 1.79 28 50.00 1.54E−09
HIS1H3C 59 56 94.92 58 98.31 6.19E−01
ANKRD1B 51 46 90.20 48 94.12 7.15E−01
Frag_01 52 0 0.00 33 63.46 1.10E−13
Frag_02 55 1 1.82 39 70.91 2.03E−15
EN1 56 15 26.79 46 82.14 3.77E−07
MSC 58 0 0.00 16 27.59 9.20E−06
GAS1 59 24 40.68 37 62.71 2.66E−02
HOXA1 57 0 0.00 13 22.81 1.00E−04
SEPT9 59 0 0.00 7 11.86 1.29E−02
FAM78B 61 0 0.00 22 36.07 4.70E−08
p Value calculated using Fisher’s exact test considering a confidence interval of 95% and two-sided p value for p[O ≤ E|O ≤ E]. 
DMR, differentially methylated region.
569Copyright © 2013 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology  •  Volume 8, Number 5, May 2013 DNA Methylation Markers for NSCLC 
containing this genomic sector is highly differentially 
methylated in NSCLC tumors. This region spans more than 
20 kb under which the EN1 gene is located. We found that 
Frag01 is highly specific with none of the control lung samples 
presenting methylation of this gene and approximately 65% 
of the tumors being methylated. This genomic region has been 
previously observed to be hypermethylated in lung tumors.59 
Other groups made similar observations in prostate60 and 
FIGURE 4.  Intensities of MSP fragments. (A) Distribution of differentially methylated regions (DMRs) selected for tumor; blue: 
control lung sample; red: tumor sample; p value is less than 0.00001 for all DMRs. (B) Intensity distribution of putative adenocar-
cinoma (ADC)-specific DMRs in ADC versus squamous cell carcinoma (SCC) tumors. (C) Intensity distribution of putative SCC-
specific DMRs in ADC versus SCC tumors. *p Value is less than 0.001; **p value is less than 0.0001. MSP, methylation-specific 
polymerase chain reaction.
TABLE 3.  Methylation Status of SCC Versus ADC for Histological Subtypes DMRs
Methylation Status Tumor
SCC ADC
Total (n) Meth (n) % Total (n) Meth (n) % p Value
ZIC4 27 23 85.19 16 16 56.25 0.0679
DOT1L 27 27 100.00 19 20 78.95 0.0101
LIMK1 25 17 68.00 18 18 33.33 0.0333
Frag_01 26 21 80.77 14 14 50.00 0.0705
Frag_02 24 20 83.33 18 11 61.11 0.1586
MSC 27 4 14.81 18 18 61.11 0.0029
GAS1 25 14 56.00 20 20 90.00 0.0197
HOXA1 25 3 12.00 19 19 42.11 0.0353
SEP9 27 2 7.41 18 18 22.22 0.1989
FAM78B 27 5 18.52 20 20 70.00 0.0007
ADC, adenocarcinoma; DMR, differentially methylated region; SCC, squamous cell carcinoma.
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colorectal cancer where they implicated it in long-range 
epigenetic silencing and suggested it as a biomarker for this 
type of tumor.61
Little is known about the role of GRIK2 in oncogenesis. 
Recently a group observed promoter hypermethylation of 
the GRIK2 gene in gastric cancer and that rescue of GRIK2 
expression in gastric cancer cells decreased cell migration.62,63 
We found that GRIK2 was hypermethylated in 90% of the 
tumors. Considering the percentages of DNA methylation 
in each sample, GRIK2 and TBX15, presented the highest 
individual tumor sensitivity and specificity of all fragments 
tested, as shown by the AUC in the ROC curves (Supplemental 
Figure 1, Supplemental Digital Content 8, http://links.lww.
com/JTO/A394). We observe TBX15 methylation in 95% of 
the tumors, with an AUC of a ROC of 0.9559, indicating high 
specificity and sensitivity for methylation in tumors.
Among the transcription factors, GATA3 presented 
methylated in almost 80% of the tumors. However, there is no 
association of methylation of this gene and NSCLC. Loss of 
GATA3 gene expression is shown to be associated with poor 
prognosis in breast cancer.64 TBX15 is another transcription 
factor gene where differential methylation of its distal promoter 
has been associated with pathological placentas.65 ONECUT2 
encodes a transcription factor containing a homeodomain and 
FIGURE 5.  Percentages of methylated DNA. (A) Distribution of differentially methylated regions (DMRs) selected for tumor; 
p value is less than 0.0001. (B) Distribution of the percentages of methylated DNA for putative adenocarcinoma (ADC)-specific 
DMRs in ADC versus squamous cell carcinoma (SCC) tumors. (C) Distribution of the percentages of methylated DNA in the 
samples for putative SCC-specific DMRs in ADC versus SCC tumors. *p value is less than 0.001; **p value is less than 0.0001.
TABLE 4.  Tumor Marker Panel
Logistic Regression PAM SVM Nearest Centroid
Five markers  
(FGF12 GATA3, RAX, TBX15, and RASSF1)
AUC 1.000 0.955 0.955 0.955
Tumor sensitivity 0.940 0.940 0.935 0.935
Tumor specificity 1.000 0.960 0.929 0.929
Training set (n = 59) Correct prediction (%) 95.00 93.00 93.00
Test set (n = 63) Correct prediction (%) 92.00 90.50 95.00
AUC, area under the curve; PAM, partitioning around medoids; SVM, support vector machines.
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its involvement in tumorigenesis is unknown. ONECUT2 has 
been reported as hypermethylated in B-cell lymphoma, where 
it was found methylated in 85% of the tumors.66 In accordance 
with this previous report, we found methylation of this gene in 
83% of our tumors. Another study investigating methylation 
in lung cancer cells lines found ONECUT2, among several 
other homeodomain genes, abnormally methylated.67
FGF12 is a member of the fibroblast growth factor 
family. FGF12 hypermethylation was observed in a myeloid 
leukemia cell line68 and it has been suggested as a candi-
date marker for SCC, where the region containing this gene 
showed different levels of methylation in SCCs and ADCs.69 
LIMK1 is a serine/threonine kinase member of the LIM family 
of proteins, known for their cysteine-rich structures with two 
zinc finger domains. A number of studies investigated the role 
of LIMK1 expression in tumor progression and invasion;70–72 
just one report directly investigated LIMK1 methylation sta-
tus, reporting higher levels of methylated LIMK1 in microdis-
sected invasive and intraductal carcinoma in breast cancer.73 
Although LIMK1 was selected as a SCC DMR, it was more 
efficient in discriminating between tumor and control lung 
samples with 50% of the tumors and only 1.7% of control 
lung samples being methylated for this gene.
For the DMRs selected based on histological subtypes, 
we found that two of the ADC DMRs (GAS1 and FAM78B), 
and one of the SCC DMRs (DOTL1) significantly differen-
tiated between the two histological subtypes. Although no 
tumor subtype panel that would give a good prediction rate 
could be built using these genes, based on our genomewide 
methylation profiles we believe it may be possible to define a 
panel of methylated genes specific for the two larger NSCLC 
subtypes (ADC and SCC). To build such a panel, identification 
of more DMRs that can significantly differentiate between the 
two subtypes will be needed. In this study we have tested five 
DMRs for each subtype. However, in our methylation profiles 
we produce a comprehensive list with DMRs that were specific 
for each subtype, where 151 genes and 93 genomic regions 
are specific for SCC, and 18 genes and 6 genomic regions for 
ADC. Genes that play specific roles in the makeup of each his-
tological subtype may be present among those. Testing more 
DMRs in a larger cohort will be needed to find the most suit-
able markers that may be used to construct a panel capable of 
correct subtype prediction.
As we observed this divergence between standard MSP 
analysis and assessment of amplification levels in their poten-
tial to discriminate tumors from control lung, we conclude 
that determination of methylation status of tumors versus nor-
mal tissues is not an all or nonmeasurement. Determining the 
levels of DNA methylation is important to properly reflect the 
potential of markers to correctly differentiate between control 
lung and tumors, which will be problematic when dealing with 
biopsies that are heterogeneous in nature. Nonetheless, our 
results indicate that a panel of markers might correctly dis-
criminate biopsies containing tumor cells from normal lung.
Here we tested 20 genes and two genomic regions from 
370 genomewide DMRs including 97 genes that were highly 
significant to distinguish either between tumor and control 
lung or ADC versus SCC.39 We have shown novel methyl-
ated genes in NSCLC that are capable of distinguishing tumor 
and control lung samples with high specificity and sensitivity, 
using either MSP band counts or DNA methylation percent-
ages. Furthermore, we presented a panel of five methylated 
genes that performs with 94% sensitivity and 96% specific-
ity in tumor prediction. This set of five methylated fragments 
correctly distinguished tumors from control lung samples in 
more than 90% of cases in our NSCLC cohort. Considering 
the sample set that we tested, these markers outperform any 
previously reported marker panel for NSCLC. This sets the 
stage for further analysis in independent sets of samples to 
establish clinical utility of this marker panel.
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